Dianthus Therapeutics (FRA:87E) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Dianthus Therapeutics's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.00.

Dianthus Therapeutics's long-term debt to total assets ratio increased from Dec. 2023 (0.00) to Dec. 2024 (0.00). It may suggest that Dianthus Therapeutics is progressively becoming more dependent on debt to grow their business.

Dianthus Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Dianthus Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dianthus Therapeutics LT-Debt-to-Total-Asset Chart

Dianthus Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

0.01

Dianthus Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial						-	-	-	-	-

Dianthus Therapeutics LT-Debt-to-Total-Asset Calculation

Dianthus Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	1.118	/	357.178
	=	0.00

Dianthus Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	1.118	/	357.178
	=	0.00

Dianthus Therapeutics (FRA:87E) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Dianthus Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Dianthus Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Dianthus Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (FRA:87E) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

DNTH:USA

Address

7 Times Square, 43rd Floor, New York, NY, USA, 10036

Website

https://www.dianthustx.com

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Dianthus Therapeutics Headlines

No Headlines